title: Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy.
abstract: Neuroendocrine tumours are a heterogeneous group of neoplasms with various clinical presentations, growth rates and responses to available therapies. Studies published in 2012 have provided insights into tumour-cell signalling that will increase our knowledge of tumour biology and molecular genetics, making it possible to personalize patient care.
authors.affiliation: Department of Endocrine Oncology, University Hospital of Uppsala, Sweden. kjell.oberg@medsci.uu.se
authors.forename: Kjell
authors.initials: K
authors.lastname: Oberg
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000068338:Everolimus; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D057285:Precision Medicine; D051499:Receptor, Fibroblast Growth Factor, Type 4 / Q000235:genetics; D015398:Signal Transduction; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; C496371:FGFR4 protein, human; D051499:Receptor, Fibroblast Growth Factor, Type 4; D020123:Sirolimus